Figure 3.

BMP9 treatment diminished amyloid plaque pathology and Aβ levels in APP/PS1 mice. (A,B) Brain sections of the cortex and hippocampus were stained with thioflavin-S, and the proportions of Aβ-positive area were calculated. Bar = 100 μm. (C,D) The Aβ plaques in the cortex and hippocampus were estimated after immunofluorescence staining with Aβ antibodies (6E10), and the proportions of positive area were calculated. Bar = 100 μm. (E–H) The levels of soluble and insoluble Aβ were measured using ELISA. (I) Representative western blots of APPfl, sAPPα, C-terminal fragment beta (CTFβ), Aβ, BACE1, IDE, NEP, RAGE, lipoprotein receptor-related protein 1 (LRP1), and GAPDH in the hippocampus homogenates from APP/PS1 mice treated with vehicle or BMP9. (J) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values are represented as the mean ± SD. Student’s t test or ANOVA followed by Bonferroni’s post hoc test. *p < 0.05, n = 6.